BR112013020802A2 - métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais - Google Patents

métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais

Info

Publication number
BR112013020802A2
BR112013020802A2 BR112013020802A BR112013020802A BR112013020802A2 BR 112013020802 A2 BR112013020802 A2 BR 112013020802A2 BR 112013020802 A BR112013020802 A BR 112013020802A BR 112013020802 A BR112013020802 A BR 112013020802A BR 112013020802 A2 BR112013020802 A2 BR 112013020802A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
nervous system
treating
reducing
Prior art date
Application number
BR112013020802A
Other languages
English (en)
Portuguese (pt)
Inventor
Yuanlong Pan
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013020802A2 publication Critical patent/BR112013020802A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/30—Oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112013020802A 2011-02-18 2012-02-07 métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais BR112013020802A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161463594P 2011-02-18 2011-02-18
PCT/US2012/024137 WO2012112340A2 (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals

Publications (1)

Publication Number Publication Date
BR112013020802A2 true BR112013020802A2 (pt) 2016-10-04

Family

ID=46673093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020802A BR112013020802A2 (pt) 2011-02-18 2012-02-07 métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais

Country Status (11)

Country Link
US (1) US20130324608A1 (enExample)
EP (1) EP2675447A4 (enExample)
JP (1) JP2014514248A (enExample)
CN (1) CN103764136A (enExample)
AU (1) AU2012218094A1 (enExample)
BR (1) BR112013020802A2 (enExample)
CA (1) CA2827715A1 (enExample)
MX (1) MX2013009544A (enExample)
RU (1) RU2013142437A (enExample)
WO (1) WO2012112340A2 (enExample)
ZA (1) ZA201306990B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014108808A2 (en) * 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US20160331712A1 (en) * 2013-12-19 2016-11-17 Tassos Georgiou Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
CN104146253A (zh) * 2014-08-13 2014-11-19 胡安然 癫痫全营养配方食品
CN110913689A (zh) * 2017-05-10 2020-03-24 罗切斯特大学 治疗神经精神病症的方法
CN109300527A (zh) * 2018-12-14 2019-02-01 苏州大学 饮食信息的推荐方法
WO2021247124A1 (en) * 2020-06-01 2021-12-09 Corona Feed Additives, L.L.C. Composition, system and method for a pig contraceptive
US20230016955A1 (en) * 2020-06-01 2023-01-19 Corona Feed Additives, L.L.C. Animal Contraceptive
MX2022015535A (es) * 2020-06-16 2023-01-30 Md Healthcare Inc Composicion para la prevencion o el tratamiento de trastornos neurologicos o mentales que comprenden vesiculas extraceluares derivadas de lactobacillus paracasei.
CN113368171A (zh) * 2021-06-18 2021-09-10 长江大学 枸杞在预防放射治疗导致的认知功能障碍药物中的应用
CN113322213B (zh) * 2021-07-09 2022-05-13 吉林大学 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883087A (en) * 1991-01-07 1999-03-16 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
CA2270795A1 (en) * 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
NZ516513A (en) * 1999-06-14 2004-03-26 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6469049B1 (en) * 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
US7563862B2 (en) * 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
AU2002336638A1 (en) * 2001-10-12 2003-04-28 Cornell Research Foundation, Inc. Reversing or preventing premature vascular senescence
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
US20040186488A1 (en) * 2003-03-17 2004-09-23 Droese Karl William Method of peripheral nerve reconstruction using a micro suction connector
US6951658B1 (en) * 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
CA2598525A1 (en) * 2005-02-22 2006-08-31 Mochida Pharmaceutical Co., Ltd. Nerve regeneration promoting agent
US20100254951A1 (en) * 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
JP2008533005A (ja) * 2005-03-11 2008-08-21 ヴァーダ コンサルティング リミテッド 生物学的活性物質の皮内的、経皮的又は経粘膜的送達のための方法
EP1915613A4 (en) * 2005-07-08 2008-11-05 Philadelphia Health & Educatio METHOD FOR MONITORING THE NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR THE TREATMENT OF DISEASES COMPRISING A COMPOSITION COMPONENT RELATED TO PHOSPHOLIPASE A2
ES2365628T3 (es) * 2005-08-26 2011-10-07 Nestec S.A. Composiciones y métodos para mejorar la integridad vascular funcional, la supervivencia celular y la reducción de la apoptosis después de un episodio isquémico en el cerebro.
WO2007022991A1 (en) 2005-08-26 2007-03-01 Nestec S.A. Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
CN101909632A (zh) * 2008-01-04 2010-12-08 雀巢产品技术援助有限公司 包含不饱和脂肪酸和一氧化氮释放化合物的组合物及其用于增强认知和相关功能的用途
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
CN103764136A (zh) 2014-04-30
JP2014514248A (ja) 2014-06-19
MX2013009544A (es) 2013-09-26
EP2675447A4 (en) 2015-04-22
WO2012112340A2 (en) 2012-08-23
EP2675447A2 (en) 2013-12-25
CA2827715A1 (en) 2012-08-23
RU2013142437A (ru) 2015-03-27
ZA201306990B (en) 2015-04-29
AU2012218094A1 (en) 2013-08-29
US20130324608A1 (en) 2013-12-05
WO2012112340A3 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
BR112013020802A2 (pt) métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais
BR112013018839A2 (pt) métodos e composições para o tratamento, a redução ou a prevenção de deterioração do sistema visual dos animais
BR112015028692A8 (pt) agente preventivo ou terapêutico para mastite de animal ruminante
BR112013027034A8 (pt) "compostos para o tratamento de transtornos neuropsiquiátricos."
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BR112014014013A2 (pt) composições e métodos para o tratamento de condições dentais
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112015006828A2 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar uma doença em um paciente em necessidade do tratamento; e método para modular a atividade de uma proteína ire1
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
MX387845B (es) Polímeros enlazados al proton para administracion oral.
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
MX382077B (es) Polimeros de union a protones para administracion oral.
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
MX2020010997A (es) Uso de derivados de isoxazolina para el tratamiento o prevencion de infestaciones por artropodos en aves de corral.
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112017001589A2 (pt) peptídeos marinhos e nucleotídeos de peixe, composições e usos dos mesmos para reduzir a glicose no sangue
MX2019002386A (es) Uso de oligosacaridos de leche humana en el engorde de terneros.
MX2020010243A (es) Composiciones bucales y metodos para animales.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]